Clinical Trial Update: Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) [Phase 1, Phase 2]

View source ↗

Summary

Recursion Pharmaceuticals is evaluating REC-4881 in people with familial adenomatous polyposis in a Phase 1/2 study that is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Adenomatous Polyposis

Drugs mentioned

• REC-4881

Snippet

Sponsor: Recursion Pharmaceuticals Inc. | Conditions: Familial Adenomatous Polyposis | Phase 1, Phase 2 | Status: RECRUITING